Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2018
Price : $35 *
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Acronyms Vaccimil
- 01 Oct 2018 Status changed from active, no longer recruiting to completed.
- 08 Jan 2018 Results (n=93) assessing immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis, were published in the Rheumatology.
- 29 Sep 2017 Planned End Date changed from 1 Nov 2015 to 31 Dec 2017.